Prostate HIFU Second Opinion: What to Clarify Before Choosing Focal Therapy Over Surgery

The folder on the kitchen table holds two very different futures. One consultation note recommends removing the whole prostate. A second, from a different specialist, suggests treating just the marked lesion with focused ultrasound and leaving the rest of the gland in place. Same MRI, same biopsy slides, same 61-year-old man, and the two plans sound like they describe two different patients.

This is the moment a prostate HIFU second opinion earns its keep. Not because one urologist is right and the other wrong, but because the choice between focal therapy and surgery is less about technology and more about how confident anyone can be in the map of your particular cancer, and about which risks you are prepared to carry.

What follows is the conversation worth having before you sign anything: how the ultrasound actually works, who usually qualifies, what the evidence can and cannot promise, and the questions that separate a reassuring appointment from a genuinely informative one.

Why a prostate HIFU second opinion is worth the delay

Localized prostate cancer rarely demands a decision this week. Guideline summaries from the NHS and the National Cancer Institute (NIH) both describe active surveillance, surgery, radiation and newer approaches such as high-intensity focused ultrasound as options that are weighed over weeks, not hours, because low- and many intermediate-risk cancers grow slowly. That breathing room is the single most useful fact in your folder.

A second opinion for HIFU is different from a second opinion for surgery. Surgery treats everything; the question is mostly whether to operate at all and what the surgeon expects for continence and erections. Focal therapy treats a portion of the gland, so the entire plan depends on the accuracy of the picture that identified that portion. Ask a second specialist to look at the same MRI and the same biopsy cores, and you are really asking them to grade the map, not just the treatment.

Three outcomes are common from that review. The second clinician agrees the disease is confined to one region and focal therapy is reasonable. Or they see additional suspicious tissue, or a higher-grade pattern on a core, and steer you toward whole-gland treatment. Or they point out that the cancer is low risk enough that watching it closely under active surveillance, with no ablation at all, is the guideline-preferred path.

Each of those answers changes the conversation. None of them can be reached without someone independent re-reading the imaging and pathology rather than summarizing the first report. When you book the appointment, request that explicitly, and ask that your slides and MRI images, not just the written reports, are sent ahead.

How prostate HIFU actually works inside the gland

High-intensity focused ultrasound, or HIFU, is a treatment that concentrates sound waves onto a small target so the tissue there heats and dies while the surrounding tissue is spared. Think of a magnifying glass focusing sunlight to a single hot point: the light passing through the lens is harmless, but the focus scorches. HIFU does this with sound instead of light.

In practice, a probe is placed in the rectum, which sits directly behind the prostate. The probe carries an ultrasound imaging element so the operator can see the gland in real time, and a treatment element that delivers the energy. Software divides the target into a grid of tiny zones, and each zone is heated in sequence. According to the NIH National Cancer Institute treatment summary, the procedure is done under anesthesia and destroys cancer cells through heat rather than radiation or cutting.

The target can be defined in different ways. Whole-gland HIFU aims to treat the entire prostate. Focal HIFU treats only the region the MRI and biopsy flagged, sometimes with a margin of normal tissue around it. Hemiablation treats one half of the gland. Your second-opinion specialist should tell you which of these is being proposed, because the side-effect profile and the follow-up plan differ considerably between them.

Two anatomical neighbors dominate the risk discussion. The urethra runs through the middle of the prostate, and the neurovascular bundles that control erections lie along its outer edges. Focal treatment exists precisely because sparing these structures is easier when less of the gland is heated. That advantage is also its central limitation: any cancer outside the heated zone is left untouched.

Focal therapy versus whole-gland treatment: the trade-off in plain terms

Radical prostatectomy is surgery that removes the entire prostate along with the seminal vesicles, and it remains one of the standard treatments for localized disease described by MedlinePlus, Mayo Clinic and the NHS. Its logic is complete: if the cancer is confined to the gland and the gland is gone, so is the cancer, and any microscopic disease the imaging missed leaves with it.

Focal therapy accepts a different bargain. It leaves most of the prostate in place to protect urinary control and sexual function, and it relies on imaging and biopsy to have found every clinically significant cancer. The NHS is candid that HIFU and similar ablative treatments are not widely available and that their long-term effectiveness compared with established treatments is still being studied. The NIH National Cancer Institute lists HIFU among approaches under evaluation rather than as a first-line standard.

So the honest framing is this. Surgery offers the most complete removal with a well-documented, decades-long track record and a well-documented set of side effects. Focal HIFU offers a gentler expected side-effect profile with a shorter track record, a real possibility of needing further treatment, and a lifelong commitment to surveillance of the remaining gland.

Neither of these is a trick answer. People who prize certainty and want one definitive treatment often lean toward surgery or radiation. People who place very high value on preserving erections and avoiding a catheter-dependent recovery, and who can live with ongoing monitoring, often explore focal options. Your second opinion should help you place yourself on that spectrum rather than simply telling you which technology the clinician prefers.

Who is usually offered focal HIFU, and who is usually asked to wait

Selection is where most of the value of focal therapy lives. Broadly, candidates share a pattern: cancer visible on a multiparametric MRI, which is a detailed scan combining several imaging sequences to highlight suspicious areas; biopsy confirmation that the significant disease sits in that visible region; and a grade that is neither so low it should simply be watched nor so high it is likely to have spread beyond the target.

Grade matters enormously. Pathologists assign a Gleason score based on how abnormal the cells look, and the NIH National Cancer Institute explains that these scores are grouped into Grade Groups from 1 (least aggressive) to 5 (most aggressive). Focal programs most often consider Grade Group 2 disease, sometimes Grade Group 3, and rarely higher, because higher grades carry a greater chance of microscopic spread the ultrasound cannot see.

Who is typically asked to wait or to consider a different path?

• People with Grade Group 1 cancer, for whom active surveillance is the guideline-preferred first approach in most cases, since treating it may add side effects without benefit.
• People whose MRI shows multiple separate lesions, or disease on both sides that cannot be captured in one treatment zone.
• People with signs the cancer has reached the capsule edge, the seminal vesicles or beyond, where whole-gland or systemic approaches are usually favored.
• People with very large prostates or heavy calcification, which can block or scatter the ultrasound beam.
• People with prior rectal surgery or certain bowel conditions, because the probe sits in the rectum.

A good second opinion states plainly which of these categories you fall into and why. If the answer is “borderline,” that is legitimate, and it usually means a repeat MRI or a targeted biopsy would sharpen the decision more than another opinion would.

Is your map good enough? Imaging and biopsy questions for a prostate HIFU second opinion

Every focal decision is only as good as the map it is drawn on. Before debating ultrasound versus scalpel, a second-opinion specialist should audit three things.

First, the MRI. Was it a multiparametric study performed on a scanner and with a protocol suited to prostate imaging, and was it read by a radiologist experienced in the PI-RADS system, the standardized 1-to-5 scale that grades how suspicious a lesion looks? Mayo Clinic describes MRI as a key tool for both locating cancer and guiding biopsy. An older scan, or one done before the biopsy caused bleeding and swelling, may need repeating.

Second, the biopsy. Were cores taken from the MRI-visible lesion using fusion guidance, meaning the MRI images were overlaid on live ultrasound to aim the needle, and were systematic cores also taken from the rest of the gland? Targeted cores tell you what the lesion is. Systematic cores tell you whether the rest of the prostate is truly clear, which is the whole premise of leaving it in place. Ask how many cores were positive, where they came from and what percentage of each core contained cancer.

Third, the pathology itself. Ask whether a second pathologist reviewed the slides. Grade Group assignments change on review more often than patients expect, and a shift from Grade Group 2 to Grade Group 3, or the discovery of a cribriform pattern (a sieve-like growth pattern linked to more aggressive behavior), can move someone out of a focal pathway.

If any of these three pieces is missing or stale, the most useful outcome of your second opinion may be a recommendation for more information rather than a recommendation for a treatment.

HIFU prostate success rate: what the evidence actually shows

People searching for a HIFU prostate success rate usually want a single percentage they can set against surgery. That number does not honestly exist yet, and a trustworthy second opinion will tell you so.

The reasons are structural rather than a matter of bad data. Focal HIFU is newer than surgery and radiation, so the follow-up in published series is measured in years rather than decades. Studies define “success” differently: some count freedom from any further treatment, others count absence of significant cancer on follow-up biopsy, others use PSA patterns that are hard to interpret when most of the gland remains. Patient selection also varies widely, and a series that treats only small Grade Group 2 lesions will report very different results from one that includes larger or higher-grade tumors.

What mainstream sources are willing to say is measured. The NHS states that HIFU’s long-term effectiveness is not yet known and that it is not widely available as a standard treatment. The NIH National Cancer Institute describes HIFU as a treatment being studied in clinical trials. Neither dismisses the approach; both decline to attach a headline figure to it.

The practical translation for your appointment: ask the clinician offering HIFU how their own program tracks outcomes, how long their follow-up runs, how they define a treatment failure, and how often people in their series have gone on to further treatment. Ask the same about surgery from the surgical team. Then compare what each is actually measuring, because the most common error in this decision is comparing a short-term focal result against a long-term surgical one as though they were the same thing.

Prostate cancer recurrence after HIFU: what "coming back" really means

Yes, prostate cancer can be found again after HIFU, and the word “recurrence” covers at least three different situations that your second opinion should tease apart.

The first is in-field persistence: cancer cells within the treated zone that survived the heating. The second is out-of-field disease: cancer elsewhere in the untreated prostate, which may have been present but invisible at the outset, or may have developed later in a gland that still carries whatever biology produced the first tumor. The third is progression beyond the prostate, which is the outcome all localized treatments are trying to prevent.

This is why follow-up after focal therapy leans on imaging and repeat biopsy rather than PSA alone. After surgery, PSA, the prostate-specific antigen protein made by prostate tissue and measured in blood, should fall to nearly undetectable levels because the tissue producing it is gone; any rise is a clear signal. After focal HIFU, the remaining healthy prostate keeps making PSA, so the level settles at a new, lower baseline rather than near zero, and the meaning of a modest rise is genuinely ambiguous.

Ask the clinician what happens if cancer is found again. Options commonly described include repeat focal treatment, whole-gland treatment such as surgery or radiation, or continued surveillance if the finding is low grade. Ask specifically whether surgery after HIFU is more technically demanding at their center, because heated tissue scars, and scarring can make later operations harder. The Mayo Clinic and NHS treatment overviews both frame these as decisions to revisit with the team rather than fixed pathways, and a good second opinion will lay out the branches before you commit to the first step.

Focal HIFU, surgery and other options side by side

A table cannot carry the nuance of a consultation, but it can show where the real differences sit. The descriptions below reflect how mainstream sources including the NHS, Mayo Clinic, Johns Hopkins and the NIH National Cancer Institute characterize each approach; they are not outcome promises.

Question	Focal HIFU	Radical prostatectomy	Active surveillance
What is treated	The MRI- and biopsy-defined region only	The whole prostate and seminal vesicles	Nothing yet; monitoring with PSA, MRI, biopsy
Evidence maturity	Shorter follow-up; described as still under study	Decades of outcome data	Well-established for low-risk disease
How progress is tracked	PSA baseline plus MRI and repeat biopsy	PSA expected near undetectable	Scheduled PSA, MRI, repeat biopsy
Typical setting	Anesthesia; often day case or overnight	Anesthesia; hospital stay	Outpatient visits
Main urinary concern	Short-term retention, irritation; stricture less commonly	Leakage, usually improving over months	Symptoms of the underlying cancer, if any
Main sexual concern	Erection changes, usually less than whole-gland treatment	Erection changes common, nerve-sparing helps	None from treatment
If cancer is found later	Repeat focal, surgery or radiation may be considered	Radiation to the prostate bed usually considered	Move to any active treatment

Radiation therapy, in external-beam and brachytherapy forms, belongs in this comparison too and is described by all the cited sources as a standard alternative to surgery. If your second opinion has not mentioned it, ask why. The point is not to add options for their own sake, but to ensure that focal HIFU is being weighed against every standard path rather than only against the one it sounds most attractive next to.

Prostate healing after HIFU: what the days and weeks afterward usually look like

Heat causes swelling before it causes shrinkage, and that sequence explains most of what people notice in the first weeks. The treated tissue becomes inflamed, the prostate temporarily enlarges, and because the urethra passes through the gland, urine flow can be obstructed. For that reason a urinary catheter, a thin tube draining the bladder, is routinely placed at the time of treatment. Focal programs usually remove it sooner than after surgery, but the precise plan varies with how much tissue was treated and belongs to your team, not to a general article.

Over the following weeks the heated tissue softens and is gradually absorbed. During that time it is common to notice urgency, a weaker stream, burning with urination, small amounts of blood or tissue debris in the urine, and mild discomfort between the legs. Ejaculate may be reduced or absent, and some people notice retrograde ejaculation, where semen travels back into the bladder rather than out. Erections may be slower to return and can improve over months as swelling around the nerve bundles subsides.

Compare this with surgery. Johns Hopkins describes a hospital stay followed by a catheter for roughly one to two weeks after radical prostatectomy, with pelvic-floor exercises to rebuild urinary control over the months that follow. Mayo Clinic notes that recovery of continence and erectile function after surgery is measured in months and depends heavily on age, baseline function and whether nerves could be spared.

Ask the focal team what their typical catheter duration is, what proportion of their patients need it replaced for retention, and when they first reassess. Ask the surgical team the same questions about leakage and pads. Recovery is a story with a timeline, and you deserve both versions in comparable detail.

Follow-up after focal therapy: PSA, MRI and the biopsy nobody mentions

Choosing focal therapy is choosing a relationship with surveillance. Because most of the prostate remains, the question “is there cancer left?” cannot be answered by a blood test alone, and a second opinion should spell out what long-term monitoring involves before you are asked to accept it.

The first layer is PSA. Mayo Clinic describes regular PSA testing after any prostate cancer treatment, often every few months at first and then less frequently. After focal HIFU the expectation is a fall to a new baseline rather than to near zero, and the team should explain what pattern would prompt concern.

The second layer is imaging. A repeat multiparametric MRI, typically scheduled in the months after treatment and then periodically, looks both at the treated zone and at the rest of the gland. Scar tissue can be hard to distinguish from residual cancer on early scans, which is one reason imaging alone is not considered sufficient.

The third layer, and the one patients are least often warned about, is a protocol biopsy. Many focal programs perform a biopsy of the treated area at a set interval regardless of PSA or MRI findings, because it is the most reliable way to confirm the treatment did what it was designed to do. That means another procedure, another anesthetic or local block, and another wait for pathology. If cancer is found, the branching decisions described earlier begin.

Ask how many years of follow-up the program recommends, what triggers a biopsy, and who coordinates it if you move or change insurers. Surgery has its own follow-up, but the questions it asks are simpler. Understanding that asymmetry is part of an informed choice, not a reason to avoid focal therapy.

Risks and side effects of HIFU and surgery, described neutrally

Every effective prostate treatment carries risk, and the honest comparison is about which risks, at what likelihood, and how reversible. The following summarizes how mainstream sources describe each approach; the frequency in your case depends on anatomy, baseline function and the extent of treatment, which is exactly what a second opinion should individualize.

For HIFU, the NHS and NIH National Cancer Institute overviews describe urinary problems as the most common early issue: retention requiring a catheter for longer than planned, urinary tract infection, urgency and irritation. Less common but more serious are urethral stricture, a narrowing of the urine tube by scar tissue that may need a procedure to open, and rectourethral fistula, an abnormal connection between the rectum and urethra. Fistula is rare with modern focal techniques but is the complication clinicians take most seriously, because it can require major surgery to repair. Erectile changes occur but are generally described as less frequent after focal than after whole-gland treatment.

For radical prostatectomy, Johns Hopkins and MedlinePlus describe urinary incontinence and erectile dysfunction as the two principal long-term risks, alongside the general risks of major surgery such as bleeding, infection and blood clots. Nerve-sparing technique reduces but does not eliminate erectile changes. Loss of ejaculate is universal after surgery because the structures that produce it are removed. Some people also notice a small loss of penile length.

Two questions cut through the generalities. Ask each team how they define and measure these outcomes in their own patients, and ask what they would do if the worst common complication happened to you. The candor of those answers usually tells you as much as the numbers.

What people often get wrong about HIFU and focal therapy

The first misunderstanding is that HIFU is “non-invasive” in the everyday sense. There is no skin incision, which is true, but a probe is placed in the rectum under anesthesia, a catheter is placed in the bladder, and the treated tissue is genuinely destroyed. Recovery is gentler than after surgery for most people, not absent.

The second is that focal therapy is a milder version of surgery with the same certainty. It is not. Surgery removes tissue the imaging could not see; focal therapy, by design, does not. The NHS statement that long-term effectiveness is still being established is not a bureaucratic hedge, it is the central caveat.

The third is that a good PSA result after HIFU means the cancer is gone. As explained earlier, the remaining prostate keeps producing PSA, so the number is a baseline to watch rather than a verdict, and follow-up MRI and biopsy carry more weight.

The fourth is the reverse error: assuming HIFU is experimental in the sense of untested. It has been studied for years, is offered within structured programs, and UK guideline bodies allow it with arrangements for audit and data collection. “Still being evaluated” and “unproven” are not the same claim.

The fifth is that choosing focal therapy closes the door on surgery. It does not close it, but it can make later surgery technically harder because of scarring, and that is worth hearing from a surgeon rather than from the team offering HIFU.

The sixth is that a second opinion is disloyal to the first doctor. Most urologists expect it for a decision like this, and many will help arrange it. The rare clinician who discourages independent review is giving you information of a different kind.

Questions to ask your care team at a prostate HIFU second opinion

Bring these written down, and bring someone to take notes. The best appointments are the ones where you leave with fewer assumptions than you arrived with.

• Have you personally reviewed my MRI images and biopsy slides, or only the reports? Do you agree with the PI-RADS score and the Grade Group?
• Is my cancer confined to one region I can see on the scan? How confident are you that the untreated parts of the gland are clear, and what is that confidence based on?
• Would active surveillance be reasonable for me instead of any treatment right now? If not, what specifically rules it out?
• Which form of HIFU are you proposing: focal, hemiablation or whole gland? How much normal tissue margin will you treat?
• How does your program define treatment failure, how long is your follow-up, and how often have your patients needed further treatment?
• What is your protocol for post-treatment PSA, MRI and biopsy, and for how many years?
• What are the most common complications in your hands, and what happens if I develop retention, a stricture or a fistula?
• If cancer is found again, what are my options, and does prior HIFU make surgery or radiation harder at this center?
• How would you expect my urinary control and erections to compare after HIFU versus after surgery, given my age and current function?
• Is there a clinical trial or registry I could join, and what would that involve?

Ask the surgical team a mirror-image set: their own complication rates, their nerve-sparing plan, what they would do about a positive margin, and what they think of focal therapy for your specific case. When both teams answer the same questions, the decision usually becomes clearer, and it remains, as it should, a decision you make together with the clinicians who will carry it out.

When to call your doctor

Whether you are still deciding, recently treated, or years into follow-up, some symptoms should not wait for the next scheduled visit. Contact your treating team the same day, or seek urgent care, if you experience any of the following.

• Inability to pass urine, or passing only small amounts with a painful, swollen lower abdomen, which can signal acute retention.
• Fever, shaking chills or feeling generally unwell after a procedure or biopsy, which can indicate infection spreading from the urinary tract.
• Heavy or persistent bleeding in the urine, especially with clots, or bleeding from the rectum.
• Urine leaking from the rectum, stool or gas passing in the urine, or new foul-smelling discharge, which are possible signs of a fistula and need prompt assessment.
• Severe pelvic or perineal pain not controlled by the measures your team advised.
• Sudden calf pain and swelling, chest pain or breathlessness after any surgery or prolonged immobility, which can indicate a blood clot.
• A catheter that stops draining, becomes blocked or falls out.
• New bone pain, unexplained weight loss or numbness and weakness in the legs at any point in follow-up.

For anything less urgent, such as slowly worsening urinary symptoms, changes in erections or a PSA result you do not understand, book a routine appointment rather than waiting for the next annual check. Mayo Clinic and MedlinePlus both stress that after any prostate cancer treatment, the follow-up schedule exists precisely so that small changes are caught early, and that patients should not hesitate to report symptoms between visits. Your treating team knows your anatomy and your treatment; they are always the right first call.

Frequently asked questions

What is the success rate of HIFU prostate therapy?

There is no single agreed figure, because published series use different definitions of success, treat different patient groups and have shorter follow-up than surgery or radiation. The NHS states that HIFU’s long-term effectiveness is not yet known, and the NIH National Cancer Institute describes it as a treatment being studied. Ask the program offering HIFU how it tracks its own outcomes, how long its follow-up runs and how often patients have needed further treatment.

Can prostate cancer come back after HIFU?

Yes. Cancer may persist within the treated zone, may be found in untreated parts of the prostate that remain in place, or may progress beyond the gland. Because healthy prostate tissue continues to make PSA after focal treatment, follow-up relies on MRI and often a planned repeat biopsy, not PSA alone. If cancer is found again, options commonly include repeat focal treatment, surgery, radiation or continued surveillance, decided with your treating team.

Is HIFU worth it for prostate cancer?

It depends on what you value and how well your cancer fits the criteria. Focal HIFU is generally described as having a gentler urinary and sexual side-effect profile than whole-gland treatment, but with less mature long-term evidence, a real chance of needing further treatment and a lifelong surveillance commitment. For people with low-risk disease, active surveillance may be preferable to any treatment. A second opinion helps place your case on that spectrum.

How long does it take for the prostate to heal after HIFU?

Healing happens in phases. Heated tissue swells first, which is why a catheter is placed at the time of treatment and why urinary irritation, urgency and small amounts of blood or debris are common in the early weeks. The treated tissue is then gradually absorbed over the following months, and erections may continue to improve as swelling settles. Exact timelines vary with how much tissue was treated, so ask your team for their typical course.

What should a prostate HIFU second opinion include?

An independent re-read of your multiparametric MRI images and biopsy slides, not just the reports; a clear statement of your Grade Group and whether the significant cancer is confined to one visible region; a view on whether active surveillance is still reasonable; a description of which form of HIFU is proposed; the program’s follow-up protocol including biopsy; and a candid account of complications and what happens if cancer is found later.

Is focal HIFU better than surgery for erections and urinary control?

Mainstream sources describe focal HIFU as generally carrying lower rates of erectile change and urinary leakage than radical prostatectomy, because less tissue near the nerve bundles and sphincter is affected. That comparison must be weighed against surgery’s more complete tissue removal and longer track record. Your own baseline function, age and anatomy influence both sets of risks, so ask each team how they would expect you specifically to recover.

Who is not a good candidate for focal HIFU?

People with Grade Group 1 disease usually do better on active surveillance; people with multiple separate lesions, cancer on both sides that cannot be treated in one zone, or signs of spread to the capsule edge or seminal vesicles are usually steered toward whole-gland treatment. Very large or heavily calcified prostates can block the ultrasound beam, and prior rectal surgery or certain bowel conditions can make probe placement unsafe. Your team makes the final call.

Does PSA go to zero after HIFU?

Not after focal HIFU. Healthy prostate tissue that remains continues to produce PSA, so the level typically falls to a new, lower baseline rather than to near undetectable, which is what happens after the whole gland is surgically removed. This makes PSA a trend to monitor rather than a verdict, and it is why focal programs add repeat MRI and often a scheduled biopsy to confirm the treated area is clear.

Can I have surgery if HIFU does not work?

Surgery and radiation are both commonly described as options after focal therapy. However, heated tissue scars, and scarring can make later prostatectomy more technically demanding and may increase the risk of urinary complications. Ask a surgeon, not only the team offering HIFU, how they approach operations after prior ablation. Knowing the realistic backup plan is a legitimate part of deciding whether to start with focal treatment.

Should I ask for a second pathology review before choosing focal therapy?

It is a reasonable request. Grade Group assignments and the presence of patterns such as cribriform growth can change when slides are reviewed by a second experienced pathologist, and a shift upward may move you out of a focal pathway. Because the entire focal strategy depends on the biopsy describing your cancer accurately, confirming that description is one of the highest-value steps you can take before any treatment decision.

References

• NHS: Prostate cancer – Treatment
• Cleveland Clinic: Prostate Cancer
• MedlinePlus: Prostate Cancer

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.